Clinical trialUNITERAREApr 3
Researchers are testing a new type of cell therapy made from umbilical cord blood to treat T-cell lymphoma that has stopped responding to other treatments. The therapy uses special immune cells called NK cells that are engineered to recognize and attack cancer cells. This is an early-stage study (Phase 1) that is now accepting patients.
WHY IT MATTERSThis trial offers a potential new treatment option for patients with relapsed or refractory T-cell lymphoma who have limited alternatives after standard therapies fail, with enrollment beginning in April 2026.
Clinical trialUNITERAREApr 3
Researchers at New York State Institute for Basic Research are testing a new treatment called transcranial direct current stimulation (tDCS) in children with autism. This treatment uses mild electrical currents applied to the scalp to potentially help with autism symptoms. The study is now accepting children to participate and will begin in April 2026.
WHY IT MATTERSThis trial offers families with autistic children a chance to explore a non-medication brain stimulation approach that may help with core autism symptoms, with enrollment actively opening at a major research institution.
Clinical trialUNITERAREApr 3
Researchers are looking for people with diabetes to test a new way to treat bad breath caused by gum disease. The treatment combines regular gum cleaning with a special light therapy that kills bacteria in the mouth. This study will help doctors understand if this combination works better than standard gum treatment alone.
WHY IT MATTERSIf you have diabetes and struggle with bad breath despite good oral hygiene, this trial offers access to an innovative combination treatment that may address both the gum disease and halitosis that often accompany diabetes.
Clinical trialCLINICALTRIALSApr 2
Researchers in France are studying a new tool called MEKANOS that measures how strong bones are and predicts fracture risk in people with fibrous dysplasia, a rare bone disease. This clinical trial involves 20 patients and aims to solve a major problem doctors face: they currently have no good way to know which patients are at highest risk of bone breaks. The study could help doctors make better treatment decisions for this condition.
WHY IT MATTERSThis trial addresses a critical gap in fibrous dysplasia care—doctors currently lack reliable tools to predict which patients will experience fractures, making this the first systematic assessment of fracture risk in this population.
Clinical trialCLINICALTRIALSApr 1
Researchers are testing a new technology called SmartMatch that helps doctors find the best cancer medicines for patients with rare brain and spinal cord tumors. The technology works by taking a small piece of tumor removed during surgery and testing it against different drugs to see which ones work best. The study wants to see if SmartMatch can complete this analysis and give doctors a report within 3 weeks of surgery. This trial is looking for 80 patients with various types of brain tumors.
WHY IT MATTERSThis trial offers patients with recurrent or advanced brain tumors access to personalized drug testing that could identify the most effective treatment for their specific tumor type within weeks of surgery.
Clinical trialCLINICALTRIALSApr 1
Researchers are looking for 3,100 people to join a study about why patients don't take their medications as prescribed. The study will test a new approach to help people stick to their treatment plans, which could improve their health and reduce unnecessary hospital visits. About half of all patients don't take their medicines the right way, and this problem gets worse when treatment also requires lifestyle changes.
WHY IT MATTERSThis trial directly addresses medication non-adherence across multiple rare disease categories, meaning patients with rare conditions could benefit from proven strategies to better manage their treatments and health outcomes.
Clinical trialCLINICALTRIALSMar 31
Researchers are building a large international database to collect information and tissue samples from children, teens, and young adults with rare brain tumors. By gathering this data from 5,800 patients, scientists hope to better understand these uncommon cancers and develop better treatments. The study is currently looking for patients to participate.
WHY IT MATTERSThis registry directly addresses rare brain tumors like astroblastoma and BCOR ITD sarcoma that have limited research data—participating patients contribute to the only large-scale international effort to understand these specific tumor types.
Clinical trialCLINICALTRIALSMar 27
Researchers are testing a new combination treatment for metastatic Merkel cell carcinoma, a rare type of skin cancer. The study combines a drug called avelumab with either a radioactive therapy or radiation treatment. The trial is currently enrolling patients and aims to see if this combination is safe and effective at fighting the cancer.
WHY IT MATTERSThis trial offers patients with metastatic Merkel cell carcinoma access to a novel combination therapy that may provide additional treatment options beyond standard care, though enrollment is currently closed.